These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7585113)

  • 21. Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance.
    Richman DD
    Adv Exp Med Biol; 1996; 394():383-95. PubMed ID: 8815703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New type of HIV drug.
    Treat Rev; 1995 Nov; (no 20):4. PubMed ID: 11363022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
    Skulnick HI; Johnson PD; Howe WJ; Tomich PK; Chong KT; Watenpaugh KD; Janakiraman MN; Dolak LA; McGrath JP; Lynn JC
    J Med Chem; 1995 Dec; 38(26):4968-71. PubMed ID: 8544171
    [No Abstract]   [Full Text] [Related]  

  • 24. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.
    Ding J; Das K; Tantillo C; Zhang W; Clark AD; Jessen S; Lu X; Hsiou Y; Jacobo-Molina A; Andries K
    Structure; 1995 Apr; 3(4):365-79. PubMed ID: 7542140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.
    Reich SH; Melnick M; Pino MJ; Fuhry MA; Trippe AJ; Appelt K; Davies JF; Wu BW; Musick L
    J Med Chem; 1996 Jul; 39(14):2781-94. PubMed ID: 8709109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 27. HIV protease inhibitors.
    Winslow DL; Otto MJ
    AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
    [No Abstract]   [Full Text] [Related]  

  • 28. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains.
    Weber J; Mesters JR; Lepsík M; Prejdová J; Svec M; Sponarová J; Mlcochová P; Skalická K; Strísovský K; Uhlíková T; Soucek M; Machala L; Stanková M; Vondrásek J; Klimkait T; Kraeusslich HG; Hilgenfeld R; Konvalinka J
    J Mol Biol; 2002 Dec; 324(4):739-54. PubMed ID: 12460574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
    Tantillo C; Ding J; Jacobo-Molina A; Nanni RG; Boyer PL; Hughes SH; Pauwels R; Andries K; Janssen PA; Arnold E
    J Mol Biol; 1994 Oct; 243(3):369-87. PubMed ID: 7525966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [AIDS: David Ho's concept of virus elimination].
    Schattenfroh S
    Dtsch Med Wochenschr; 1997 Jun; 122(24):A7. PubMed ID: 9229558
    [No Abstract]   [Full Text] [Related]  

  • 31. Saquinavir: an HIV proteinase inhibitor.
    Bragman K
    Adv Exp Med Biol; 1996; 394():305-17. PubMed ID: 8815695
    [No Abstract]   [Full Text] [Related]  

  • 32. Synthesis of potent and orally active HIV-protease inhibitors.
    Capraro HG; Bold G; Fässler A; Cozens R; Klimkait T; Lazdins J; Mestan J; Poncioni B; Rösel JL; Stover D; Lang M
    Arch Pharm (Weinheim); 1996 Jun; 329(6):273-8. PubMed ID: 8767110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral dynamics in human immunodeficiency virus type 1 infection.
    Wei X; Ghosh SK; Taylor ME; Johnson VA; Emini EA; Deutsch P; Lifson JD; Bonhoeffer S; Nowak MA; Hahn BH
    Nature; 1995 Jan; 373(6510):117-22. PubMed ID: 7529365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving HIV treatment step by step.
    Smart T
    GMHC Treat Issues; 1996 Aug; 10(8):1-3. PubMed ID: 11363716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
    Balzarini J
    Verh K Acad Geneeskd Belg; 1995; 57(6):575-600. PubMed ID: 8686372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pseudo-symmetrical difluoroketones. Highly potent and specific inhibitors of HIV-1 protease.
    Sham HL; Betebenner DA; Wideburg N; Saldivar AC; Kohlbrenner WE; Craig-Kennard A; Vasavanonda S; Kempf DJ; Clement JJ; Erickson JE
    FEBS Lett; 1993 Aug; 329(1-2):144-6. PubMed ID: 8354389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.
    Mitsuya H; Maeda K; Das D; Ghosh AK
    Adv Pharmacol; 2008; 56():169-97. PubMed ID: 18086412
    [No Abstract]   [Full Text] [Related]  

  • 38. The daunting challenge of keeping HIV suppressed.
    Cohen J
    Science; 1997 Jul; 277(5322):32-3. PubMed ID: 9229768
    [No Abstract]   [Full Text] [Related]  

  • 39. Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors-In Silico Activity Prediction.
    Dąbrowska A; Pieńko T; Taciak P; Wiktorska K; Chilmonczyk Z; Mazurek AP; Stasiulewicz A
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent developments of peptidomimetic HIV-1 protease inhibitors.
    Qiu X; Liu ZP
    Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.